{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:14:46Z","timestamp":1761765286884,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.urology.2009.11.083","type":"journal-article","created":{"date-parts":[[2010,3,23]],"date-time":"2010-03-23T06:23:40Z","timestamp":1269325420000},"page":"1138-1143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["The Use of Zoledronic Acid in Men Receiving Androgen Deprivation Therapy for Prostate Cancer With Severe Osteopenia or Osteoporosis"],"prefix":"10.1016","volume":"75","author":[{"given":"Steven C.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmala","family":"Bhoopalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Moritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padmini","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"VanVeldhuizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy K.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizy","family":"Thottapurathu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harinder","family":"Garewal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart R.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenic J.","family":"Reda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2009.11.083_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x","article-title":"Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial","volume":"79","author":"Adib","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2009.11.083_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eururo.2003.10.003","article-title":"Role of bisphosphonates in prostate cancer","volume":"45","author":"Saad","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib4","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0022-5347(05)65060-4","article-title":"Osteoporosis in men treated with androgen deprivation therapy for prostate cancer","volume":"167","author":"Ross","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3","article-title":"Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma","volume":"79","author":"Townsend","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2009.11.083_bib6","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0090-4295(02)01579-0","article-title":"Osteoporosis during androgen deprivation therapy for prostate cancer","volume":"60","author":"Smith","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.11.083_bib8","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","article-title":"Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer","volume":"166","author":"Oefelein","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.juro.2006.08.089","article-title":"Bone health in men receiving androgen deprivation therapy for prostate cancer","volume":"177","author":"Eastham","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.juro.2007.09.028","article-title":"Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy","volume":"179","author":"Israeli","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2009.11.083_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1359\/jbmr.1997.12.1.24","article-title":"Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation","volume":"12","author":"Ray","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.urology.2009.11.083_bib13","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1097\/01.ju.0000097351.48848.1f","article-title":"Management of bone loss in men with prostate cancer","volume":"170","author":"Higano","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.urology.2004.03.036","article-title":"Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy","volume":"64","author":"Conde","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.11.083_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.aje.a008920","article-title":"Risk factors for osteoporotic fractures in elderly men","volume":"144","author":"Nguyen","year":"1996","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.urology.2009.11.083_bib16","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib17","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.juro.2009.07.046","article-title":"Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy","volume":"182","author":"Bhoopalam","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib18","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2009.11.083_bib19","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0022-5347(18)31245-X","article-title":"Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients requiring androgen deprivation therapy for prostate cancer","volume":"177","author":"Wadhaw","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0022-5347(18)33782-0","article-title":"The effect of zoledronic acid on bone density in men with prostate cancer undergoing continuous androgen deprivation therapy: a two year, perspective, randomized, multicenter study comparing zoledronic acid to no treatment","volume":"177","author":"Casey","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib21","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","article-title":"Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer","volume":"176","author":"Ryan","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3816\/CGC.2007.n.003","article-title":"The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy","volume":"5","author":"Israeli","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urology.2009.11.083_bib23","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2009.11.083_bib24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","article-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study","volume":"179","author":"Smith","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2009.11.083_bib25","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","article-title":"Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2009.11.083_bib26","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","article-title":"Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer","volume":"69","author":"Morote","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.11.083_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1210\/edrv-16-1-87","article-title":"Osteoporosis in men","volume":"16","author":"Orwoll","year":"1995","journal-title":"Endocr Rev"},{"key":"10.1016\/j.urology.2009.11.083_bib28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.urology.2007.03.026","article-title":"Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy","volume":"70","author":"Ryan","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.11.083_bib29","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2009.11.083_bib30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1078-1439(03)00108-X","article-title":"The potential benefits of dietary and\/or supplemental calcium and vitamin D","volume":"21","author":"Moyad","year":"2003","journal-title":"Urol Oncol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429510000452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429510000452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:54:02Z","timestamp":1758765242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429510000452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0090429510000452"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2009.11.083","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of Zoledronic Acid in Men Receiving Androgen Deprivation Therapy for Prostate Cancer With Severe Osteopenia or Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2009.11.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}